NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

Featured Updates to the NCCN Guidelines

View More View Less
  • 1 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
  • 2 Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;
  • 3 University of Colorado Cancer Center;
  • 4 Huntsman Cancer Institute at the University of Utah;
  • 5 Fox Chase Cancer Center;
  • 6 Robert H. Lurie Comprehensive Cancer Center of Northwestern University;
  • 7 Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;
  • 8 The University of Texas MD Anderson Cancer Center;
  • 9 Dana-Farber/Brigham and Women’s Cancer Center;
  • 10 Duke Cancer Institute;
  • 11 Moffitt Cancer Center;
  • 12 UT Southwestern Simmons Comprehensive Cancer Center;
  • 13 Yale Cancer Center/Smilow Cancer Hospital;
  • 14 UCSF Helen Diller Family Comprehensive Cancer Center;
  • 15 O'Neal Comprehensive Cancer Center at UAB;
  • 16 Roswell Park Comprehensive Cancer Center;
  • 17 Fred & Pamela Buffett Cancer Center;
  • 18 Massachusetts General Hospital Cancer Center;
  • 19 University of Wisconsin Carbone Cancer Center;
  • 20 University of Michigan Rogel Cancer Center;
  • 21 Stanford Cancer Institute;
  • 22 Vanderbilt-Ingram Cancer Center;
  • 23 City of Hope National Medical Center;
  • 24 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;
  • 25 The University of Tennessee Health Science Center;
  • 26 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;
  • 27 UC San Diego Moores Cancer Center;
  • 28 Memorial Sloan Kettering Cancer Center;
  • 29 Mayo Clinic Cancer Center;
  • 30 Abramson Cancer Center at the University of Pennsylvania;
  • 31 UCLA Jonsson Comprehensive Cancer Center; and
  • 32 National Comprehensive Cancer Network.
Restricted access

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.

  • 1.

    Siegel RL, Miller KD, Fuchs HE, . Cancer statistics, 2021. CA Cancer J Clin 2021;71:733.

  • 2.

    Howlader N, Noone AM, Krapcho M, , eds. SEER Cancer Statistics Review, 1975-2017. Accessed January 10, 2021. Available at: https://seer.cancer.gov/csr/1975_2017/

    • Search Google Scholar
    • Export Citation
  • 3.

    Nadal E, Massuti B, Dómine M, . Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother 2019;68:341352.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Garon EB, Hellmann MD, Rizvi NA, . Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 2019;37:25182527.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Leighl NB, Hellmann MD, Hui R, . Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med 2019;7:347357.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Lin JJ, Cardarella S, Lydon CA, . Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol 2016;11:556565.

  • 7.

    Pacheco JM, Gao D, Smith D, . Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. J Thorac Oncol 2019;14:691700.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Shaw AT, Riely GJ, Bang YJ, . Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol 2019;30:11211126.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Singhi EK, Horn L, Sequist LV, . Advanced non-small cell lung cancer: sequencing agents in the EGFR-mutated/ALK-rearranged populations. Am Soc Clin Oncol Educ Book 2019;39:e187e197.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Zhao D, Chen X, Qin N, . The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer. Sci Rep 2017;7:40374.

  • 11.

    Johung KL, Yeh N, Desai NB, . Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 2016;34:123129.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Reck M, Rodríguez-Abreu D, Robinson AG, . Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 2019;37:537546.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Antonia SJ, Borghaei H, Ramalingam SS, . Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol 2019;20:13951408.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Ettinger DS, Wood DE, Aisner DL, . NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2.2021. Accessed January 10, 2021. To view the most recent version, visit NCCN.org

  • 15.

    Shaw AT, Bauer TM, de Marinis F, . First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 2020;383:20182029.

  • 16.

    Wolf J, Seto T, Han JY, . Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med 2020;383:944957.

  • 17.

    Gainor JF, Curigliano G, Kim DW, . Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 9515.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Drilon A, Oxnard GR, Tan DSW, . Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med 2020;383:813824.

  • 19.

    Smit EF, Nakagawa K, Nagasaka M, . Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01 [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 9504.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Tsurutani J, Iwata H, Krop I, . Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discov 2020;10:688701.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Wu YL, Tsuboi M, He J, . Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020;383:17111723.

  • 22.

    Benayed R, Offin M, Mullaney K, . High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin Cancer Res 2019;25:47124722.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Mazieres J, Drilon A, Lusque A, . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 2019;30:13211328.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Soria JC, Ohe Y, Vansteenkiste J, . Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113125.

  • 25.

    Lisberg A, Cummings A, Goldman JW, . A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol 2018;13:11381145.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Camidge DR, Dziadziuszko R, Peters S, . Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol 2019;14:12331243.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Gainor JF, Shaw AT, Sequist LV, . EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 2016;22:45854593.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Tsao MS, Kerr KM, Kockx M, . PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint Phase 2 Project. J Thorac Oncol 2018;13:13021311.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Hirsch FR, McElhinny A, Stanforth D, . PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol 2017;12:208222.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Lam VK, Tran HT, Banks KC, . Targeted tissue and cell-free tumor DNA sequencing of advanced lung squamous-cell carcinoma reveals clinically significant prevalence of actionable alterations. Clin Lung Cancer 2019;20:3036.e3.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Sands JM, Nguyen T, Shivdasani P, . Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Lung Cancer 2020;140:3541.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Sholl LM, Aisner DL, Varella-Garcia M, . Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the Lung Cancer Mutation Consortium experience. J Thorac Oncol 2015;10:768777.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Camidge DR, Kim HR, Ahn MJ, . Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. J Clin Oncol 2020;38:35923603.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Camidge DR, Kim HR, Ahn MJ, . Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med 2018;379:20272039.

  • 35.

    D’Angelo A, Sobhani N, Chapman R, . Focus on ROS1-positive non-small cell lung cancer (NSCLC): crizotinib, resistance mechanisms and the newer generation of targeted therapies. Cancers (Basel) 2020;12:12.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36.

    Drilon A, Siena S, Dziadziuszko R, . Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:261270.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Mu Y, Yang K, Hao X, . Clinical characteristics and treatment outcomes of 65 patients with BRAF-mutated non-small cell lung cancer. Front Oncol 2020;10:603.

  • 38.

    Auliac JB, Bayle S, Do P, . Efficacy of dabrafenib plus trametinib combination in patients with BRAF V600E-mutant NSCLC in real-world setting: GFPC 01-2019. Cancers (Basel) 2020;12:12.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39.

    Khunger A, Khunger M, Velcheti V. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience. Ther Adv Respir Dis 2018;12:1753466618767611.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Reck M, Rodríguez-Abreu D, Robinson AG, . Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:18231833.

  • 41.

    Mok TSK, Wu YL, Kudaba I, . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019;393:18191830.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Hellmann MD, Ciuleanu TE, Pluzanski A, . Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018;378:20932104.

  • 43.

    Hellmann MD, Paz-Ares L, Bernabe Caro R, . Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 2019;381:20202031.

  • 44.

    Gandhi L, Rodríguez-Abreu D, Gadgeel S, . Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:20782092.

  • 45.

    Herbst RS, Giaccone G, de Marinis F, . Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med 2020;383:13281339.

  • 46.

    Socinski MA, Jotte RM, Cappuzzo F, . Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018;378:22882301.

  • 47.

    Paz-Ares L, Luft A, Vicente D, . Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018;379:20402051.

  • 48.

    Sesma A, Pardo J, Cruellas M, . From tumor mutational burden to blood T cell receptor: looking for the best predictive biomarker in lung cancer treated with immunotherapy. Cancers (Basel) 2020;12:12.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 49.

    Borghaei H, Langer CJ, Paz-Ares L, . Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: a pooled analysis of 3 randomized controlled trials. Cancer 2020;126:48674877.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Sholl LM, Hirsch FR, Hwang D, . The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol 2020;15:14091424.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 51.

    Offin M, Rizvi H, Tenet M, . Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin Cancer Res 2019;25:10631069.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Rizvi H, Sanchez-Vega F, La K, . Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol 2018;36:633641.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Carbone DP, Reck M, Paz-Ares L, . First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 2017;376:24152426.

  • 54.

    Marabelle A, Fakih M, Lopez J, . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:13531365.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Antonia SJ, Villegas A, Daniel D, . Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379:23422350.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2635 2635 1234
PDF Downloads 1155 1155 574
EPUB Downloads 0 0 0